
    
      This prospective, randomized, double-blind, placebo-controlled release study will enroll
      approximately 300 healthy adults 18 to 49 years of age (not yet reached their 50th birthday).
      Eligible participants will be randomly assigned in a 4:1 fashion to receive a single dose of
      monovalent vaccine or placebo by intranasal spray. Randomization will be stratified by site.
      This study will be conducted at 2 sites in the United States of America. Each participant
      will receive 1 dose of investigational product on Day 1. The duration of study participation
      for each participant is the time from study vaccination through 180 days after study
      vaccination.
    
  